Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany.

ABSTRACT:

Background

There is a lack of real-world data on the use of targeted cancer drugs requiring molecular tumor diagnostics in the treatment of lung cancer in Germany.

Aims

We aimed to characterize the use of such drugs in lung cancer patients based on longitudinal analyses.

Methods and results

Using the GePaRD database (claims data from ~20% of the German population) we identified lung cancer patients diagnosed in 2016 based on a previously developed algorithm and followed them until death, end of continuous insurance, or end of 2019. We determined the proportion of patients treated with at least one of the drugs under study (EGFR, ALK, and BRAF inhibitors). We described these patients regarding demographic characteristics, treatment patterns, and overall survival. We in

SUBMITTER: Rischke N 

PROVIDER: S-EPMC11654761 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature